COMMENTARY Basic Medical

OPEN ACCESS

Tissue-specific cancer evolution: Deciphering deterministic rules to shape precision medicine

Yanxia Chen[1,2] **and Cuiping Yang**[1,2,*]

[1]The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200030, China

[2]Shanghai Key Laboratory of Embryo Original Diseases, Shanghai 200030, China

*Correspondence: cuipingyang@sjtu.edu.cn

Received: March 26, 2026; Accepted: April 9, 2026; Published Online: April 13, 2026; https://doi.org/10.59717/j.xinn-drugdisc.2026.100014

Citation: Chen Y. and Yang C. (2026). Tissue-specific cancer evolution: Deciphering deterministic rules to shape precision medicine. *The Innovation Drug Discovery* **1**:100014.

Tumor initiation and progression are strongly influenced by tissue context, with oncogenes such as Kirsten rat sarcoma viral oncogene homolog (KRAS) exhibiting remarkable tissue-specificity in their oncogenic potency and patterns of genetic collaboration. Despite decades of cancer genomics research, the fundamental determinants governing these context-dependent differences remain incompletely understood. Mueller et al. address this critical gap by developing the Mouse Cancer Cell line Atlas (MCCA), a comprehensive resource comprising 590 rigorously characterized cancer cell lines across 46 disease subtypes. Through the integration of multi-omics analyses, functional validation, and cross-species comparisons, this study delineates the core principles of tissue-specific cancer evolution, with a focus on KRAS-driven malignancies.[1] The findings not only advance our mechanistic understanding of cancer genome dynamics but also establish a framework for translating biological insights into rational drug development strategies.

A key innovation of this work is the establishment of the MCCA, the first pan-cancer cell line resource for mice that rivals human counterparts for the Cancer Cell Line Encyclopedia (CCLE). Unlike conventional mouse models, the MCCA provides multi-layered datasets for each cell line, including genomics, transcriptomics, histopathology, epithelial-mesenchymal transition (EMT) phenotypes, and immunophenotypes. Critically, the researchers developed computational tools to infer strain background, major histocompatibility complex (MHC) haplotypes, and biological sex from genomic data, enabling precise matching of cell lines to immunocompetent recipients. This feature addresses a longstanding limitation in preclinical research, where mismatched immunophenotypes often confound transplantation studies. The MCCA's interactive web portal (www.mcca.tum.de) further enhances accessibility, allowing researchers to explore genotype-phenotype relationships and identify mouse models that recapitulate specific human cancer subtypes.[1]

The study uncovers three fundamental principles governing tissue-specific cancer evolution. First, mutant KRAS dosage gain via allelic imbalance exerts cell-type-specific effects with distinct timing across tissues: in the pancreas, increased KRAS dosage is an early event driving acinar cell developmental reprogramming, whereas in the intestine and lung, it occurs later during carcinoma progression. Second, tissue-specific evolutionary requirements select for distinct KRAS-collaborating alterations: wingless-related integration site (WNT) pathway activation is essential for blocking intestinal differentiation, while cyclin-dependent kinase inhibitor 2A (CDKN2A) inactivation is critical for pancreatic cancer initiation. Third, context-dependent epistatic interactions between KRAS and tumor suppressors determine the frequency, zygosity, and acquisition chronology of cancer gene alterations. For example, CDKN2A homozygous deletion is nearly ubiquitous in KRAS-mutant pancreatic cancer (82%) but rare in lung (5%) and intestinal (11%) cancers, reflecting tissue-specific chromatin states that modulate CDKN2A's tumor-suppressive function.[1]

Mueller et al. propose a "deterministic framework" in which intrinsic tissue properties guide the evolution of cancer. This model is thought-provoking but invites comparison with existing theories. The conventional clonal evolution model emphasizes stochastic mutation acquisition and selection, while lineage plasticity models highlight the role of cellular reprogramming and microenvironmental cues. The deterministic model differs by positing that tissue-intrinsic factors strongly constrain which genetic alterations occur and in what order. However, several questions remain. First, the cross-sectional approach fails to elucidate whether observed patterns stem from deterministic rules or probabilistic events governed by differential selective pressures. Second, while CDKN2A repression represents a striking illustrative case, it remains undetermined whether comparable regulatory mechanisms extend to other tumor suppressor genes across diverse tissue contexts. Third, the model may underestimate the role of stochastic events and microenvironmental heterogeneity, which can drive divergent outcomes even within identical tissues. An integrative view incorporating both deterministic constraints and stochastic variability may ultimately prove more accurate.

A key finding is the demonstration that Polycomb-mediated repression of CDKN2A underpins its tissue-specific activity. In the intestine, high H3K27me3 occupancy silences CDKN2A, reducing selective pressure for its inactivation. In contrast, active chromatin states in the pancreas render CDKN2A responsive to KRAS-induced senescence, driving strong selection for its loss. Additionally, the study reveals tissue-specific differences in the chronological order of genetic events: CDKN2A inactivation precedes KRAS dosage gain in the pancreas, whereas the reverse occurs in the lung and intestine. These findings challenge the concept of universal cancer progression models and support a deterministic framework in which intrinsic tissue properties guide evolutionary trajectories.[1] Notably, similar tissue-specific reprogramming by oncogenic KRAS has been observed in lung adenocarcinoma, where KRAS (G12D) drives lepidic adenocarcinoma through stem-cell reprogramming of differentiated AT1 cells, highlighting the broader relevance of cell-of-origin effects.[2]

The MCCA and its derived insights hold promise for mitigating a critical challenge in oncology drug development, where translational failure arises from suboptimal preclinical models. By identifying tissue-specific dependencies, the study enables the selection of a rational target. For instance, pancreatic cancer's reliance on KRAS dosage gain and CDKN2A loss suggests that combinatorial therapies targeting KRAS signaling and senescence bypass mechanisms could be particularly effective for this refractory disease. Conversely, intestinal cancers' dependence on WNT pathway activation highlights WNT inhibitors as promising agents for KRAS-mutant colorectal cancer, a subset with limited treatment options. The MCCA further facilitates preclinical testing by providing immunocompetent models with defined MHC haplotypes and "effective" tumor mutational burden (pTMB), enabling more accurate prediction of immunotherapy responses.[1] This builds on prior success with syngeneic mouse models derived from genetic glioblastoma models, which have proven valuable for testing treatments in intact immune microenvironments.[3]

The discovery of tissue-specific genetic alteration patterns offers opportunities to develop context-aware biomarkers. For example, KRAS allelic imbalance status could serve as a predictive marker for response to KRAS inhibitors, as increased dosage correlates with enhanced MAPK pathway activation and poorer patient outcomes. Similarly, CDKN2A chromatin state profiling may identify patients most likely to benefit from therapies targeting Polycomb repressive complexes (PRCs). Such biomarkers can stratify patient populations in clinical trials, reducing attrition rates by ensuring therapies are tested in the most responsive subsets.[1]

Tissue-specific evolutionary rules also shed light on the mechanisms of resistance. The study shows that KRAS dosage gain and CDKN2A loss contribute to treatment resistance by enhancing oncogenic signaling and bypassing tumor suppression. This suggests that combination strategies co-targeting these pathways could prevent or reverse resistance. For example, PRMT5 inhibitors, which exhibit synthetic lethality in MTAP-deleted cancers, might be combined with KRAS G12C inhibitors to address resistance in lung cancer. Additionally, the MCCA's ability to model different evolutionary stages allows researchers to identify resistance drivers emerging in specific tissue contexts and enables the development of preemptive combination therapies.[1]

Compared with conventional preclinical drug development approaches, such as human cancer cell lines (e.g., CCLE) with poor standardization, patient-derived organoids (PDOs) lacking reproducibility, genetically engineered mouse models (GEMMs) that are costly and low-throughput, and AI-driven in silico tools requiring experimental validation, the MCCA offers several practical advantages. It provides a standardized panel of 590 rigorously quality-controlled murine cell lines spanning 46 cancer subtypes, ensuring consistent and reproducible mechanistic dissection of tumor evolution. Comprehensive immunophenotypic annotations (including MHC haplotypes and tumor mutational burden) enable reliable immuno-oncology research and immunotherapy response prediction, addressing a critical gap in most traditional models. Moreover, the MCCA excels at modeling tissue-specific tumor progression and drug resistance, particularly for KRAS-driven cancers, while supporting high-throughput screening and cross-species



Figure 1. A framework for tissue-specific cancer evolution and drug development based on the MCCA This schematic outlines the mechanisms underlying tissue-specific KRAS-driven tumor evolution (top), the multi-layered preclinical resource of the MCCA (bottom left), and translational strategies for future drug development (bottom right). Tissue-specific variations in the timing of KRAS dosage acquisition and the frequency of CDKN2A inactivation reflect context-dependent genetic and epigenetic interactions. The MCCA encompasses 590 cell lines spanning 46 disease subtypes, annotated with multi-omic and immune phenotypic profiles. Proposed strategies include multi-model integration, establishment of preclinical-clinical feedback loops, and improved tumor microenvironment modeling, aimed at accelerating the development of personalized therapies for refractory malignancies.

comparative analysis to mitigate translational risks from species differences. It also resolves key limitations of conventional tools, such as the lack of standardized microenvironmental and immune context in cell lines and the inefficiency of GEMMs for large-scale studies. Nevertheless, as the original authors acknowledge, the MCCA is predominantly focused on KRAS-driven models and common mouse strains, with limited in vivo validation of immunophenotype predictions; these caveats should be considered when generalizing its findings.

Future drug development could build on these strengths by taking several steps. These include expanding the MCCA to cover more oncogenes (e.g., EGFR, BRAF) and rare cancers to validate the generality of tissue-specific evolutionary rules; integrating single-cell multi-omics to further decipher intratumoral heterogeneity and subclonal dynamics, enhancing mechanistic insights; adopting a multi-model integration strategy by combining the MCCA's standardized screening with PDOs for clinical translatability validation, GEMMs for in vivo efficacy assessment, and AI to streamline candidate selection and optimize the research pipeline; establishing preclinical-clinical feedback loops to calibrate models with clinical data; and enhancing the MCCA's microenvironment simulation via co-culture or microfluidics to further narrow the translational gap. These steps will accelerate the development of personalized and combination therapies, addressing unmet needs within refractory malignancies (Figure 1).

Mueller et al.'s work represents an important advance in cancer research by deciphering deterministic rules of tissue-specific evolution.[1] The MCCA resource, combined with the mechanistic insights in this study, provides a roadmap for precision oncology drug development. By recognizing that cancer evolution is guided by intrinsic tissue properties and context-dependent genetic interactions, researchers and drug developers can design more rational preclinical studies and clinical trials. Ultimately, this work moves us closer to a future where cancer therapies are tailored not only to the tumor genotype but also to the tissue of origin, maximizing efficacy and minimizing unnecessary treatments. The MCCA illustrates the value of comprehensive preclinical resources in bridging the gap between basic research and clinical translation, building on the utility of syngeneic models in preclinical testing[3] and the importance of cell-of-origin effects in cancer biology.[2]

REFERENCES

1. Mueller, S., de Andrade Krätzig, N., Tschurtschenthaler, M., et al. (2026). A disease model resource reveals core principles of tissue-specific cancer evolution. Nature. DOI: 10.1038/s41586-026-10187-2.
2. Juul, N.H., Yoon, J.K., Martinez, M.C., et al. (2023). KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogramming. *Nature* **619**(7971):860–867. DOI:10.1038/s41586-023-06324-w
3. Costa, B., Fletcher, M.N.C., Boskovic, P., et al. (2021). A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human Tumors. Cancers (Basel) **13**(2). DOI: 10.3390/cancers13020230.

FUNDING AND ACKNOWLEDGMENTS

This work was supported by the National Natural Science Foundation of China (82173110) and the grants from the Program of Shanghai Academic/Technology Research Leader (22XD1423900), and the Eastern Talent Plan Leading Project 2024. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

AUTHOR CONTRIBUTIONS

All authors contributed to the manuscript and approved the final version.

DECLARATION OF INTERESTS

The authors declare no competing interests.